Abstract: The present disclosure relates to a plurality of light-emitting materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound or a specific combination of compounds according to the present disclosure as a host material and/or a dopant material, it is possible to provide an organic electroluminescent device having improved driving voltage, luminous efficiency and/or lifetime properties compared to conventional organic electroluminescent devices.

Abstract: This invention relates to triarylamine compounds and compositions including such compounds, that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a compound or composition. The triarylamine compound can be present as a hole transport material in a hole transport layer. The triarylamine compound can also be present in a photoactive layer in combination with an organometallic compound capable of electroluminescence having an emission maximum between 380 and 750 nm.

Abstract: This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R2 are an N-heterocycle; R3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Abstract: There is provided a compound having Formula II In Formula II: R1-R4 are the same or different at each occurrence and can be D, alkyl, silyl, aryl, deuterated alkyl, deuterated silyl, or deuterated aryl; a and c are the same or different and are an integer from 0-5; and b and d are the same or different and are an integer from 0-4.

Abstract: This invention relates to triarylamine compounds and compositions including such compounds, that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a compound or composition. The triarylamine compound can be present as a hole transport material in a hole transport layer. The triarylamine compound can also be present in a photoactive layer in combination with an organometallic compound capable of electroluminescence having an emission maximum between 380 and 750 nm.

Abstract: This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R2 are an N-heterocycle; R3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Abstract: This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R2 are an N-heterocycle; R3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Abstract: There is provided a compound having Formula II In Formula II: R1-R4 are the same or different at each occurrence and can be D, alkyl, silyl, aryl, deuterated alkyl, deuterated silyl, or deuterated aryl; a and c are the same or different and are an integer from 0-5; and b and d are the same or different and are an integer from 0-4.

Abstract: There is provided a compound having Formula II In Formula II: R1 can be alkyl having 1-6 carbons, silyl having 3-6 carbons, or a deuterated analog thereof; R2 can be alkyl, silyl, aryl, or a deuterated analog thereof; a and c are the same or different and are an integer from 0-4; and b is an integer from 0-5.

Abstract: This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R2 are an N-heterocycle; R3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Abstract: Antagonists at the NMDA receptor complex which are benz?b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Abstract: Antagonists at the NMDA receptor complex which are benz[b]azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.

Abstract: Antagonists at the NMDA receptor complex which are benz b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.